StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a report issued on Tuesday morning. The firm issued a sell rating on the biotechnology company’s stock.
Aptevo Therapeutics Price Performance
Shares of NASDAQ:APVO opened at $0.33 on Tuesday. The company’s 50 day moving average is $0.67 and its two-hundred day moving average is $3.66. Aptevo Therapeutics has a 52 week low of $0.28 and a 52 week high of $80.96.
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($9.95) earnings per share for the quarter, beating the consensus estimate of ($14.10) by $4.15. As a group, research analysts forecast that Aptevo Therapeutics will post -8.86 earnings per share for the current year.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Further Reading
- Five stocks we like better than Aptevo Therapeutics
- Quiet Period Expirations Explained
- Sales Breakout Sends This Semiconductor Stock to Record High
- Insider Trades May Not Tell You What You Think
- Surprise Buying Opportunity on This Dividend Aristocrat
- Why Invest in 5G? How to Invest in 5G Stocks
- New Theme Park Powerhouse: Merger Creates Industry-Leading Stock
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
